Low CD34+cells, high neutrophils and the metabolic syndrome are associated with an increased risk of venous thromboembolism

The relationship between MetS (metabolic syndrome), levels of circulating progenitor/immune cells and the risk of VTE (venous thromboembolism) has not yet been investigated. We studied 240 patients with previous VTE and 240 controls. The presence of MetS was identified according to NCEP ATP III guidelines and flow cytometry was used to quantify circulating CD34+ cells. VTE patients showed higher BMI (body mass index), waist circumference, triacylglycerol (triglyceride) levels, blood glucose, hs-CRP (high-sensitivity C-reactive protein) and lower HDL-C (high-density lipoprotein cholesterol) levels. The prevalence of MetS was significantly higher in VTE (38.3%) than in control individuals (21.3%) with an adjusted OR (odds ratio) for VTE of 1.96 (P=0.002). VTE patients had higher circulating neutrophils (P<0.0001), while the CD34+ cell count was significantly lower among patients with unprovoked VTE compared with both provoked VTE (P=0.004) and controls (P=0.003). Subjects were also grouped according to the presence/absence of MetS (MetS+ or MetS-) and the level (high/low) of both CD34+ cells and neutrophils. Very high adjusted ORs for VTE were observed among neutrophils_high/MetS+ (OR, 3.58; P<0.0001) and CD34+_low/MetS+ (OR, 3.98; P<0.0001) subjects as compared with the neutrophils_low/MetS- and CD34+_high/MetS- groups respectively. In conclusion, low CD34+ blood cell count and high circulating neutrophils interplay with MetS in raising the risk for venous thromboembolic events

Dizionario di Medicina Moderna

none33noneM. Vanoli; I. Apollonio; F. Auxilia; L. Barozzi; G. Basilisco; V. Bellia; I. Casagranda; G.L. Castoldi; N. Ceserani; R. Delle Piane; G. Federici; A. Filippi; L. Franchini; A. Gevorgyan; S. Girlanda; A. Lania; V. Locatelli; E. Mozzi; N. Natale; C. Pagano; A. Pagni; M. Peduzzi; G.M. Rigolin; D. Rodriguez; M. Rossato; G. Scaramellini; M. Signorelli; A. Spagnolo; G. Traisci; V. Trevisan; A. Trinchieri; M. Vanoli; S. VeraldiM., Vanoli; I., Apollonio; F., Auxilia; L., Barozzi; G., Basilisco; V., Bellia; I., Casagranda; Castoldi, Gianluigi; N., Ceserani; R., Delle Piane; G., Federici; A., Filippi; L., Franchini; A., Gevorgyan; S., Girlanda; A., Lania; V., Locatelli; E., Mozzi; N., Natale; C., Pagano; A., Pagni; M., Peduzzi; Rigolin, Gian Matteo; D., Rodriguez; M., Rossato; G., Scaramellini; M., Signorelli; A., Spagnolo; G., Traisci; V., Trevisan; A., Trinchieri; M., Vanoli; S., Verald

Pain assessment and management in haemophilia: A survey among Italian patients and specialist physicians

Introduction: Persons with haemophilia (PWH) experience recurrent joint bleeding which leads from early synovitis to irreversible joint damage. Pain strongly affects patients’ quality of life, as PWH suffer from acute pain associated with haemarthroses and chronic pain due to arthritic and degenerative complications. Aim: To investigate pain issues among PWH and their treaters in Italy. Methods: Persons with haemophilia and specialist physicians responded to a survey focused on pain characteristics, assessment, and management by phone call and online, respectively. Results: One hundred and nineteen patients (76% severe haemophilia, 61% ≥18&nbsp;years) and 44 physicians were involved. Pain was reported by 61% of PWH; among those who did not experience pain, 70% were children on prophylaxis. Patients described pain as chronic (71%), acute (69%) or postoperative (8%), and rated it as severe in 65% of cases. Clinicians reported lower percentages of patients with pain (46%), classified as chronic (58%), acute (33%) or postoperative (21%), half using specific scales. Pain was systematically investigated by treaters according to 36% of patients. Paracetamol was largely the most prescribed first-line pain therapy (89%), as well the most employed analgesic by PWH (51%), who also used non-steroidal anti-inflammatory drugs (24%), cyclo-oxygenase-2 inhibitors (21%) or opioids (26%). To manage pain, 61% of clinicians stated to collaborate with other specialists. Physiotherapy was often suggested but less frequently used by PWH. Conclusions: Pain is under-recognized and unsatisfactorily addressed by haemophilia treatment centre (HTC) clinicians, with discrepant management compared to PWH responses. Education in systematic pain assessment and multidisciplinary treatment and development of management guidelines are highly needed

Nédemax mese (Leucoselect, Lymphaselect, Bromelain) in the treatment of chronic venous disease: a multicenter , obbservational study

BACKGROUND: Chronic venous disease (CVD)is major health concern; however,there remains a need to improve treatment approaches.Nédemax Mese , a nutritional supplementation consisting of Leucoselect 300 mg,Lymphaselect 100 mg and Bromelain 100 mg, is a patented formulation thah may have a role in the treatment of CVD. In this prospective , multicenter study conducted at 54 Italian centers, we investigated the effectiveness of Nédemax Mese in a large sample of CVD patients

Nédemax® Mese (Leucoselect®, Lymphaselect®, Bromelain) in the treatment of chronic venous disease: a multicenter, observational study

BACKGROUND: Chronic venous disease (CVD)is major health concern; however,there remains a need to improve treatment approaches.Nédemax Mese , a nutritional supplementation consisting of Leucoselect 300 mg,Lymphaselect 100 mg and Bromelain 100 mg, is a patented formulation thah may have a role in the treatment of CVD. In this prospective , multicenter study conducted at 54 Italian centers, we investigated the effectiveness of Nédemax Mese in a large sample of CVD patients

Pain assessment and management in Italian Haemophilia Centres

Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the severity of arthropathy in persons with haemophilia (PWH), some develop degenerative joint changes, associated with significant pain. The aim of this survey was to investigate the management and perception of pain among Italian physicians who treat PWH

The FOOT FragmentatiOn Of Target Experiment

International audienceIn proton-therapy clinical practice a constant RBE equal to 1.1 is adopted, regardless of the demonstrated RBE variations, which depends on physical and biological parameters. Among other mechanisms, nuclear interactions might influence the proton-RBE due to secondary heavier particles produced by target fragmentation that can significantly contribute to the total dose: an un-wanted and undetermined increase of normal tissues complications probability may occur. The FOOT experiment is designed to study these processes. Target ($^{16}$O,$^{12}$C) fragmentation induced by 150 − 250 M eV proton beam will be studied via inverse kinematic approach, where $^{16}$O and $^{12}$C therapeutic beams, with the same kinetic energy per nucleon of the proton, collide on graphite and hydrocarbons target to provide the cross section on Hydrogen (to explore also the projectile fragmentation). The detector design, the performances and expected resolution results obtained form Monte Carlo study, based on the FLUKA code will be presented

Development and characterization of a Δ E-TOF detector prototype for the FOOT experiment

This paper describes the development and characterization of a ΔE-TOF detector composed of a plastic scintillator bar coupled at both ends to silicon photomultipliers. This detector is a prototype of a larger version which will be used in the FOOT (FragmentatiOn Of Target) experiment to identify the fragments produced by ion beams accelerated onto a hydrogen-enriched target. The final ΔE-TOF detector will be composed of two layers of plastic scintillator bars with orthogonal orientation and will measure, for each crossing fragment, the energy deposited in the plastic scintillator (ΔE), the time of flight (TOF), and the coordinates of the interaction position in the scintillator. To meet the FOOT experimental requirements, the detector should have energy resolution of a few percents and time resolution of 70 ps, and it should allow to discriminate multiple fragments belonging to the same event. To evaluate the achievable performances, the detector prototype was irradiated with protons of kinetic energy in the 70–230 MeV range and interacting at several positions along the bar. The measured energy resolution σΔE∕ΔE was 6–14%, after subtracting the fluctuations of the deposited energy. A time resolution σ between 120 and 180 ps was obtained with respect to a trigger detector. A spatial resolution σ of 1.9 cm was obtained for protons interacting at the center of the bar